Abstract 524P
Background
Small cell lung cancer (SCLC) has limited treatment options, especially as the number of treatment lines increases. This study investigated the standard of care (SOC) for advanced SCLC in Taiwan.
Methods
This retrospective cohort study used linked data from Taiwan Cancer Registry (TCR), National Health Insurance Research Database, and Death Registry (2014–2019). Cancer-related information was collected from TCR: age, sex, year of initial diagnosis, initial treatment status, smoking status, and genetic mutations. The algorithm for building lines of pharmacological therapies for SCLC was based on NCCN guidelines, published studies and expert opinions. Median overall survival (OS), with 95% confidence interval (CI) was estimated using the Kaplan-Meier method, referencing from the initiation of each therapy line until death or the end of 2019. Patients with documented extensive stage (ES) were analyzed in the same manner as patients with stage IV SCLC.
Results
We identified 3134 stage IV SCLC patients with a median age 69.9 years at diagnosis. Of these patients, 12% were female, and 83% were smokers. Among 2237 patients who initiated first-line (1L) therapy, 1048 (47%) patients received 2+ lines of therapy, and 349 (16%) received 3+ lines. The predominant treatments were cisplatin plus etoposide in 1L (61%) and topotecan in 2L (58%) whereas 3L treatment options included platinum plus etoposide (38%), topotecan (22%), and etoposide only (17%) regimens. Median OS with 95% CI were 8.4 (8.1–8.7) months after 1L therapy; 4.9 (4.5–5.4) months after 2L therapy, and 4.4 (3.9–5.5) months after 3L therapy. Similar characteristics and treatment regimens were observed among the 1866 patients with documented extensive-stage SCLC, with median OS of 8.6 (8.3–9.1) months after 1L therapy, 5.0 (4.5–5.6) months after 2L therapy, and 5.4 (4.3–6.2) months after 3L therapy.
Conclusions
In Taiwan, treatment regimens for advanced SCLC follow NCCN guidelines; real-world overall survival rates are consistent with published data. These results show that an urgent unmet need exists for SCLC patients. Further study is needed on immunotherapy’s effect on SCLC SOC, as our study predates insurance coverage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Amgen.
Disclosure
Y. Yang, W-J. Chen, C-H. Chang: Financial Interest, Personal, Full or part-time Employment: Amgen. All other authors have declared no conflict of interest.
Resources from the same session
372P - Effectiveness of HAN-MI-RADS (head and neck molecular imaging-reporting and data system) criterion in head and neck squamous cell carcinoma post concurrent chemoradiotherapy
Presenter: Manoj Gupta
Session: Poster Display
Resources:
Abstract
373P - Investigating the impact of treatment on geriatric patients with locally advanced head and neck squamous cell carcinoma
Presenter: Yen Ting Liu
Session: Poster Display
Resources:
Abstract
374P - Immunohistochemical evaluation of oral lichen planus: A prospective clinical study
Presenter: Saravanan Sampoornam Pape
Session: Poster Display
Resources:
Abstract
375P - Survival and prognostic factors of head and neck squamous cell carcinoma patients treated with either definitive CCRT or post operative CCRT with platinum-based chemotherapy in Rajavithi hospital, Thailand
Presenter: wanit samadee
Session: Poster Display
Resources:
Abstract
376P - Nutrition as an independent prognostic factor in locally advanced nasopharyngeal carcinoma: A retrospective cohort study and propensity score-matched analysis
Presenter: haizhen yi
Session: Poster Display
Resources:
Abstract
377P - Oropharyngeal squamous cell carcinomas in Indian population: P16 positivity and treatment outcomes following chemoradiotherapy
Presenter: Parth Verma
Session: Poster Display
Resources:
Abstract
378P - A real-world retrospective analysis of the efficacy of pembrolizumab combined with chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA HNSCC)
Presenter: zhu Liu
Session: Poster Display
Resources:
Abstract
379P - Nimotuzumab in combination with chemoradiation for patients with intermediate stage and locally advanced nasopharyngeal carcinoma: A retrospective comparative analysis using 5-year real-world survival data
Presenter: Andhika Rachman
Session: Poster Display
Resources:
Abstract
380P - An epidemiological analysis on the prevalence of oral cancer and its awareness among Irula tribes of South India
Presenter: Delfin Lovelina Francis
Session: Poster Display
Resources:
Abstract
381P - P16INK4 over-expression, early stages, keratinization, and surgical margin-free status are associated with better prognosis of oral squamous cell carcinoma (OSCC)
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract